Soluble Biomarkers of Osteoporosis and Osteoarthritis, from Pathway Mapping to Clinical Trials: An Update

Előd Ernő Nagy,1 Csilla Nagy-Finna,1,2 Horațiu Popoviciu,2 Béla Kovács1 1Department of Biochemistry and Environmental Chemistry, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, Târgu Mureș, Romania; 2Department M4,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nagy EE, Nagy-Finna C, Popoviciu H, Kovács B
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	osteoarthritis osteoporosis biomarkers Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/274438b71e2b49499af736e01e377ed4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:274438b71e2b49499af736e01e377ed4
record_format	dspace
spelling	oai:doaj.org-article:274438b71e2b49499af736e01e377ed42021-12-02T10:34:08ZSoluble Biomarkers of Osteoporosis and Osteoarthritis, from Pathway Mapping to Clinical Trials: An Update1178-1998https://doaj.org/article/274438b71e2b49499af736e01e377ed42020-04-01T00:00:00Zhttps://www.dovepress.com/soluble-biomarkers-of-osteoporosis-and-osteoarthritis-from-pathway-map-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Előd Ernő Nagy,1 Csilla Nagy-Finna,1,2 Horațiu Popoviciu,2 Béla Kovács1 1Department of Biochemistry and Environmental Chemistry, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, Târgu Mureș, Romania; 2Department M4, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, Târgu Mureș, Romania; Rheumatology Clinic, Clinical Emergency Hospital, Târgu Mureș, RomaniaCorrespondence: Előd Ernő NagyDepartment of Biochemistry and Environmental Chemistry, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, Gheorghe Marinescu Street No. 38, Târgu Mureș 540139, RomaniaTel +40-265 215551 int. 187Email elod.nagy@umfst.roAbstract: Serum biomarkers of osteoarticular diseases have been in the limelight of current clinical research trends. Laboratory validation of defined and candidate biomarkers for both osteoarthritis and osteoporosis is of key importance for future decisional algorithms in the diagnosis, monitoring, and prognosis of these diseases. The current guidelines recommend the use of collagen degradation remnants, eg, CTX-I and CTX-II, in the complementary diagnosis of both osteoporosis and osteoarthritis. Besides the collagen degradation markers, enzymes that regulate bone and articular metabolism are useful in the clinical evaluation of osteoarticular pathologies. Along these, several other recommended and new nominee molecules have been recently studied. Wnts and Wnt-related molecules have a cardinal role in the bone-joint homeostasis, making them a promising target not only for pharmaceutical modulation, but also to be considered as soluble biomarkers. Sclerostin and dickkopf, two inhibitor molecules of the Wnt/β-catenin signaling, might have a dual role in the assessment of the clinical manifestations of the osteoarticular unit. In osteoarthritis, besides fragments of collagen type II many pathway-related molecules have been studied and proposed for biomarker validation. The most serious limitation is that a significant proportion of studies lack statistical power due to the reduced number of cases enrolled. Serum biomarkers of bone and joint turnover markers represent an encouraging possibility for the diagnosis and prognosis of osteoarticular diseases, although further studies and laboratory validations should be carried out as to solely rely on them.Keywords: osteoarthritis, osteoporosis, biomarkersNagy EENagy-Finna CPopoviciu HKovács BDove Medical PressarticleosteoarthritisosteoporosisbiomarkersGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 15, Pp 501-518 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	osteoarthritis osteoporosis biomarkers Geriatrics RC952-954.6
spellingShingle	osteoarthritis osteoporosis biomarkers Geriatrics RC952-954.6 Nagy EE Nagy-Finna C Popoviciu H Kovács B Soluble Biomarkers of Osteoporosis and Osteoarthritis, from Pathway Mapping to Clinical Trials: An Update
description	Előd Ernő Nagy,1 Csilla Nagy-Finna,1,2 Horațiu Popoviciu,2 Béla Kovács1 1Department of Biochemistry and Environmental Chemistry, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, Târgu Mureș, Romania; 2Department M4, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, Târgu Mureș, Romania; Rheumatology Clinic, Clinical Emergency Hospital, Târgu Mureș, RomaniaCorrespondence: Előd Ernő NagyDepartment of Biochemistry and Environmental Chemistry, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, Gheorghe Marinescu Street No. 38, Târgu Mureș 540139, RomaniaTel +40-265 215551 int. 187Email elod.nagy@umfst.roAbstract: Serum biomarkers of osteoarticular diseases have been in the limelight of current clinical research trends. Laboratory validation of defined and candidate biomarkers for both osteoarthritis and osteoporosis is of key importance for future decisional algorithms in the diagnosis, monitoring, and prognosis of these diseases. The current guidelines recommend the use of collagen degradation remnants, eg, CTX-I and CTX-II, in the complementary diagnosis of both osteoporosis and osteoarthritis. Besides the collagen degradation markers, enzymes that regulate bone and articular metabolism are useful in the clinical evaluation of osteoarticular pathologies. Along these, several other recommended and new nominee molecules have been recently studied. Wnts and Wnt-related molecules have a cardinal role in the bone-joint homeostasis, making them a promising target not only for pharmaceutical modulation, but also to be considered as soluble biomarkers. Sclerostin and dickkopf, two inhibitor molecules of the Wnt/β-catenin signaling, might have a dual role in the assessment of the clinical manifestations of the osteoarticular unit. In osteoarthritis, besides fragments of collagen type II many pathway-related molecules have been studied and proposed for biomarker validation. The most serious limitation is that a significant proportion of studies lack statistical power due to the reduced number of cases enrolled. Serum biomarkers of bone and joint turnover markers represent an encouraging possibility for the diagnosis and prognosis of osteoarticular diseases, although further studies and laboratory validations should be carried out as to solely rely on them.Keywords: osteoarthritis, osteoporosis, biomarkers
format	article
author	Nagy EE Nagy-Finna C Popoviciu H Kovács B
author_facet	Nagy EE Nagy-Finna C Popoviciu H Kovács B
author_sort	Nagy EE
title	Soluble Biomarkers of Osteoporosis and Osteoarthritis, from Pathway Mapping to Clinical Trials: An Update
title_short	Soluble Biomarkers of Osteoporosis and Osteoarthritis, from Pathway Mapping to Clinical Trials: An Update
title_full	Soluble Biomarkers of Osteoporosis and Osteoarthritis, from Pathway Mapping to Clinical Trials: An Update
title_fullStr	Soluble Biomarkers of Osteoporosis and Osteoarthritis, from Pathway Mapping to Clinical Trials: An Update
title_full_unstemmed	Soluble Biomarkers of Osteoporosis and Osteoarthritis, from Pathway Mapping to Clinical Trials: An Update
title_sort	soluble biomarkers of osteoporosis and osteoarthritis, from pathway mapping to clinical trials: an update
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/274438b71e2b49499af736e01e377ed4
work_keys_str_mv	AT nagyee solublebiomarkersofosteoporosisandosteoarthritisfrompathwaymappingtoclinicaltrialsanupdate AT nagyfinnac solublebiomarkersofosteoporosisandosteoarthritisfrompathwaymappingtoclinicaltrialsanupdate AT popoviciuh solublebiomarkersofosteoporosisandosteoarthritisfrompathwaymappingtoclinicaltrialsanupdate AT kovacsb solublebiomarkersofosteoporosisandosteoarthritisfrompathwaymappingtoclinicaltrialsanupdate
_version_	1718397045439463424

Soluble Biomarkers of Osteoporosis and Osteoarthritis, from Pathway Mapping to Clinical Trials: An Update

Ejemplares similares